SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	L-Carnitine / Levocarnitine	NAD+	AICAR (Acadesine)
Research Topic	Clinical / Endocrine Pharmacology	Mitochondrial / Metabolic Research	Mitochondrial / Metabolic Research
Pharmacology	Endogenous nutrient and prescription active ingredient in product-specific contexts	Endogenous redox cofactor and metabolic co-substrate; not a peptide	Investigational purine nucleoside analogue / adenosine-regulating agent; not a peptide
PrimeCore Class	Class AApproved in a bounded context	Class CExperimental / limited evidence	Class BInvestigational
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade CEarly human evidence	Grade BStrong controlled human evidence
Evidence boundary	L-Carnitine / Levocarnitine is classified here as Endogenous nutrient and prescription active ingredient in product-specific contexts. Authorised levocarnitine products exist for defined deficiency-related contexts, while wellness and body-composition claims require separate evidence. U.S. prescription labels exist for defined levocarnitine products; that status does not authenticate a catalogue vial or any Lipo-C blend. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	An endogenous redox cofactor, not a peptide; evidence depends strongly on precursor, formulation and route.	A nucleoside analogue and AMPK-related research compound, not a peptide; clinical and anti-doping contexts must be separated.
Unknowns	Insufficient data in the current dataset	whether direct NAD+ improves any patient-important clinical outcome tissue distribution and cellular uptake across routes and formulations long-term safety, interaction and repeated-exposure risks comparability among IV preparations and proprietary oral formulations whether biomarker increases translate into better function or healthspan current Thailand, EU and UK product-specific regulatory status pending direct verification status and results of ongoing or recently completed formulation-specific trials	long-term safety outside short perioperative research settings human risk-benefit for weight, metabolic or performance claims effects of repeated exposure on purine, glucose and lipid metabolism comparability of research-grade AICAR, acadesine formulations and online products current product-specific marketing-authorisation status in Thailand, the EU and UK current US compounding-list status under a substance-specific FDA review
Limitations	L-Carnitine / Levocarnitine molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	The direct-human literature is small, short and dominated by pharmacokinetic, biomarker or tolerability endpoints. The 2019 IV study had only eight treated participants and three controls; the 2026 IV comparison was retrospective with six direct-NAD+ clients; and the oral RCT tested one proprietary formulation for five days. Route, formulation and precursor studies cannot be pooled as a single NAD+ efficacy claim.	Strong controlled human evidence exists only in a narrow CABG setting and culminated in a negative confirmatory trial. Older meta-analytic and post-hoc signals must be interpreted in light of RED-CABG. Popular performance claims are based mainly on mouse work. Mechanistic studies also show that AICAR is not selective for AMPK, limiting simple pathway-based conclusions.
Sources	DailyMed · L-Carnitine / Levocarnitine human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026 https://pubmed.ncbi.nlm.nih.gov/31572171/ https://pubmed.ncbi.nlm.nih.gov/41704678/ https://pubmed.ncbi.nlm.nih.gov/42530810/ https://clinicaltrials.gov/study/NCT07336836 https://pubmed.ncbi.nlm.nih.gov/39531138/ https://products.mhra.gov.uk/ https://www.ema.europa.eu/en/medicines/download-medicine-data https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list https://www.wada-ama.org/sites/default/files/2024-08/tue_physician_guidelines_iv_infusion_-_version_8.0_-_august_2024.pdf	https://precision.fda.gov/uniisearch/srs/unii/53ief47846 https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=203105 https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=341011 https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://clinicaltrials.gov/study/NCT00872001 https://pubmed.ncbi.nlm.nih.gov/7818622/ https://pubmed.ncbi.nlm.nih.gov/7574044/ https://pubmed.ncbi.nlm.nih.gov/9002496/ https://pubmed.ncbi.nlm.nih.gov/22782417/ https://pubmed.ncbi.nlm.nih.gov/7744080/ https://pubmed.ncbi.nlm.nih.gov/18674809/ https://pubmed.ncbi.nlm.nih.gov/27103440/ https://pubmed.ncbi.nlm.nih.gov/34064363/ https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://products.mhra.gov.uk/ https://www.ema.europa.eu/en/medicines/download-medicine-data https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.